Sonoma Pharmaceuticals, INC. (SNOA) — 8-K Filings

8-K Filings (24)

• Sonoma Pharmaceuticals Enters Manufacturing Agreement — Apr 9, 2026 Risk: medium
  On April 8, 2026, Sonoma Pharmaceuticals, Inc. entered into a material definitive agreement, specifically a Manufacturing and Supply Agreement. The filing detai
• Sonoma Pharmaceuticals Reports Officer and Director Changes — Oct 23, 2025 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on October 23, 2025, reporting changes effective October 18, 2025. The filing covers the departure of directors or cer
• Sonoma Pharmaceuticals Reports Director/Officer Changes & Financials — Oct 9, 2025 Risk: medium
  Sonoma Pharmaceuticals, Inc. filed an 8-K on October 9, 2025, reporting changes in its board of directors and officers, along with updates to compensatory arran
• Sonoma Pharmaceuticals Files 8-K, Confirms Nasdaq Listing — Sep 29, 2025 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on September 29, 2025, reporting its status as an emerging growth company. The filing indicates that the company's com
• Sonoma Pharmaceuticals Files 8-K — Sep 26, 2025 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on September 26, 2025, reporting the entry into a material definitive agreement and the filing of financial statements
• Sonoma Pharmaceuticals Files 8-K on Shareholder Votes — Aug 29, 2025 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on August 29, 2025, reporting on matters submitted to a vote of security holders as of August 27, 2025. The filing det
• 8-K Filing — Apr 28, 2025
• 8-K Filing — Apr 7, 2025
• Sonoma Pharmaceuticals Enters Material Definitive Agreement — Mar 25, 2025 Risk: medium
  Sonoma Pharmaceuticals, Inc. entered into a Material Definitive Agreement on March 21, 2025. The filing also includes financial statements and exhibits related
• Sonoma Pharmaceuticals Enters Material Definitive Agreement — Jan 30, 2025 Risk: medium
  Sonoma Pharmaceuticals, Inc. announced on January 29, 2025, that it entered into a Material Definitive Agreement. The company, formerly known as Oculus Innovati
• Sonoma Pharmaceuticals Reports Director and Officer Changes — Jan 3, 2025 Risk: medium
  Sonoma Pharmaceuticals, Inc. filed an 8-K on January 3, 2025, reporting changes effective January 2, 2025. The filing covers the departure and election of direc
• Sonoma Pharmaceuticals Terminates Material Agreement — Nov 21, 2024 Risk: medium
  Sonoma Pharmaceuticals, Inc. announced on November 21, 2024, the termination of a material definitive agreement. The filing does not specify the counterparty or
• Sonoma Pharmaceuticals Enters Material Definitive Agreement — Oct 22, 2024 Risk: medium
  Sonoma Pharmaceuticals, Inc. announced on October 17, 2024, that it entered into a material definitive agreement. The company, formerly known as Oculus Innovati
• Sonoma Pharmaceuticals Files 8-K — Sep 20, 2024 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on September 20, 2024, reporting on other events and financial statements. The company, formerly known as Oculus Innov
• Sonoma Pharmaceuticals Files 8-K with Key Corporate Updates — Aug 28, 2024 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on August 23, 2024, reporting on several key events. These include amendments to its Articles of Incorporation or Byla
• Sonoma Pharmaceuticals Files 8-K — Aug 23, 2024 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on August 22, 2024, reporting other events and financial statements. The company, formerly known as Oculus Innovative
• Sonoma Pharmaceuticals Files 8-K — Aug 21, 2024 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on August 21, 2024, reporting a material definitive agreement and financial statements. The filing date indicates even
• Sonoma Pharmaceuticals Files 8-K — Jun 27, 2024 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on June 27, 2024, reporting other events and financial statements. The company, formerly known as Oculus Innovative Sc
• Sonoma Pharmaceuticals Files 8-K — Apr 9, 2024 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on April 9, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
• Sonoma Pharmaceuticals Files 8-K — Apr 2, 2024 Risk: low
  Sonoma Pharmaceuticals, Inc. filed an 8-K on April 2, 2024, reporting on Regulation FD disclosures and financial statements/exhibits. The company, formerly Ocul
• Sonoma Pharmaceuticals Faces Delisting Notice — Mar 22, 2024 Risk: high
  Sonoma Pharmaceuticals, Inc. filed an 8-K on March 22, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company was for
• Sonoma Pharmaceuticals Enters Material Definitive Agreement — Mar 8, 2024 Risk: medium
  Sonoma Pharmaceuticals, Inc. announced on March 8, 2024, that it entered into a Material Definitive Agreement. The filing does not provide specific details abou
• Sonoma Pharma Confirms Nasdaq Listing for SNOA Common Stock — Jan 10, 2024
  Sonoma Pharmaceuticals, Inc. filed an 8-K on January 10, 2024, to disclose that its Common Stock, trading under the symbol SNOA, is registered on The Nasdaq Sto
• Sonoma Pharma Enters Material Definitive Agreement on Jan 5 — Jan 9, 2024
  Sonoma Pharmaceuticals, Inc. filed an 8-K on January 9, 2024, reporting a material definitive agreement entered into on January 5, 2024. This filing indicates a

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX